American College of Cardiology 75th Annual Scientific Session & Expo (ACC.26)
New Orleans, Louisiana, US 28 March 2026 - 30 March 2026
Statin-ezetimibe holds slight advantage over PCSK9is in ACS
In a systematic review and network meta-analysis (NMA), a statin-ezetimibe combination yields a more favourable LDL-C reduction and a positive trend in atherosclerotic plaque regression compared with PCSK9 inhibitors (PCSK9is) alone in individuals with acute coronary syndrome (ACS).
Statin-ezetimibe holds slight advantage over PCSK9is in ACS
24 Apr 2026
Mavacamten reduces blood flow obstruction in adolescents with HCM
Treatment with mavacamten, compared with placebo, results in significantly greater reduction in left ventricular outflow tract (LVOT) obstruction over 28 weeks among adolescent patients with obstructive hypertrophic cardiomyopathy (HCM), as shown in the SCOUT-HCM trial.
Mavacamten reduces blood flow obstruction in adolescents with HCM
14 Apr 2026
More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients
An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.
More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients
13 Apr 2026
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.